Chinese maker of home medical devices — glucose meters, lancets and disposable diagnostic consumables.
Chinese maker of home medical devices — glucose meters, lancets and disposable diagnostic consumables.
Sells branded home-use devices largely through online shops and pharmacy chains, with marketing and sales channels a major cost. Disposable test strips used with its meters bring repeat purchases.
In one line: A Chinese home-diagnostics device maker.
Moat: none (distribution). Competitive home-diagnostics category with several similar domestic makers.
Headquarters: Zhuhai, Guangdong, China · Employees: 5,081
Size Cofoe Medical Technology (301087.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.60B, the 1432nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥47.43 on 18 Nov 2026.
Performance Over six months the shares fell 6.0%, against +1.9% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 33.5% over the last twelve months (peer median +8.6%); the operating margin is 9.9% (peer median 10.6%).
Valuation It trades at 25.1× forward earnings against a peer median of 22.0× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.6 points above its cost of capital (9.1% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.18B | CN¥3.37B | CN¥2.98B | CN¥2.84B | CN¥2.97B |
| Revenue growth | — | +13% | +5% | -4% | — |
| Gross profit | CN¥2.37B | CN¥1.65B | CN¥1.42B | CN¥1.12B | CN¥1.09B |
| EBITDA | n/a | CN¥528M | CN¥491M | CN¥366M | CN¥376M |
| Net income | CN¥417M | CN¥372M | CN¥312M | CN¥254M | CN¥302M |
| Free cash flow | CN¥259M | CN¥557M | CN¥557M | CN¥64.2M | -CN¥478M |
| Capital expenditure | CN¥141M | CN¥178M | CN¥120M | CN¥373M | CN¥640M |
| Total debt | CN¥1.33B | CN¥917M | CN¥1.00B | CN¥744M | CN¥577M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cofoe Medical Technology 301087.SZ | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% |
| Sinocare 300298.SZ | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% |
| Andon Health 002432.SZ | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301087.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.6% | -0.1% | 4th lowest of 21 |
| 6-month return | -6.0% | +1.9% | 10th lowest of 21 |
| Distance from 52-week high | -25.9% | -25.6% | 11th highest of 21 |
| Revenue growth (TTM) | +33.5% | +8.6% | 5th highest of 21 |
| Operating margin | 9.9% | 10.6% | 11th highest of 21 |
| Forward P/E | 25.1× | 22.0× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 11.2% | 10.7% | 8th most demanding of 16 |
| Growth delivered (Del g) | +7.4% | +14.0% | 4th lowest of 16 |
| Hurdle (Req g minus delivered) | +3.8 pp | -8.8 pp | 4th most demanding of 16 |
| ROIC minus cost of capital | +2.6 pp | +2.3 pp | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |